e-Drug3D

1851

PIBRENTASVIR

INN
PIBRENTASVIR

cas 1353900-92-1

CLASS

ANTIINFECTIVES
TREATMENT OF HEPATITIS C VIRUS (HCV)
NS3/4A PROTEASE INHIBITOR

ROUTE (list)

ORAL

ATC code

J05AP57

PK parameters

Tmax 5 HOUR
Cmax 98.9 NANOMOLAR
PPB 99.9 PERCENT
t1/2 13 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET NS5A PROTEASE

DrugCentral

Unknown

Download SDF file

Carbamic acid, N,N'-[[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)-1-piperidinyl]phenyl]-2,5-pyrrolidinediyl]bis[(6-fluoro-1H-benzimidazole-5,2-diyl)-(2S)-2,1-pyrrolidinediyl[(1S)-1-[(1R)-1-methoxyethyl]-2-oxo-2,1-ethanediyl]]]bis-, C,C'-dimethyl ester

Formula:
C57H65F5N10O8

Calculated chemical properties:

MW 1113.19
NB_atoms 80
XLogP 9.45
PSA 186.23
NB_HD 4
NB_HA 18
fsp3 0.47
Lipinski(0=no;1=yes) 0

FDA
NDA 209394 (label) INN (GLECAPREVIR ; PIBRENTASVIR) MAVYRET (ABBVIE) APPROVAL= AP YEAR= 2017
NDA 215110 (label) INN (GLECAPREVIR ; PIBRENTASVIR) MAVYRET (ABBVIE) APPROVAL= AP YEAR= 2021